OncoQuest Pharmaceuticals Inc Cash Flow-to-Debt Ratio
OncoQuest Pharmaceuticals Inc cash flow-to-debt ratio. OncoQuest Pharmaceuticals Inc (078590) has a Cash Flow-to-Debt Ratio of -0.07x as of March 2026, meaning its operating cash flow of ₩-1.42 Billion could theoretically repay 0% of its total liabilities (₩19.38 Billion) in one year. Check OncoQuest Pharmaceuticals Inc (078590) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of OncoQuest Pharmaceuticals Inc (2014–2025)
Cash flow-to-debt ratio of OncoQuest Pharmaceuticals Inc from 2014 to 2025. Historical debt coverage capacity for OncoQuest Pharmaceuticals Inc across 10 annual periods. Check 078590 capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
OncoQuest Pharmaceuticals Inc Cash Flow-to-Debt Ratio by Year (2014–2025)
OncoQuest Pharmaceuticals Inc cash flow-to-debt ratio by year from 2014 to 2025. Year-by-year debt coverage analysis for OncoQuest Pharmaceuticals Inc. For the full cash flow conversion analysis, see 078590 cash flow metrics.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.01x | ₩485.35 Million | ₩32.66 Billion | ▼ -89.7% |
| 2024 | 0.14x | ₩3.96 Billion | ₩27.40 Billion | ▼ -86.1% |
| 2023 | 1.04x | ₩11.19 Billion | ₩10.77 Billion | ▲ +4188.5% |
| 2022 | -0.03x | ₩-236.91 Million | ₩9.33 Billion | ▲ +71.8% |
| 2019 | -0.09x | ₩-4.26 Billion | ₩47.21 Billion | ▼ -375.5% |
| 2018 | 0.03x | ₩1.44 Billion | ₩43.95 Billion | ▼ -93.0% |
| 2017 | 0.47x | ₩4.79 Billion | ₩10.21 Billion | ▼ -3.9% |
| 2016 | 0.49x | ₩3.54 Billion | ₩7.26 Billion | ▲ +20.4% |
| 2015 | 0.41x | ₩2.79 Billion | ₩6.89 Billion | ▲ +283.5% |
| 2014 | 0.11x | ₩1.02 Billion | ₩9.61 Billion | — |